MedPath

Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension

Not Applicable
Recruiting
Conditions
Pulmonary Hypertension
Interventions
Device: Nasal high-flow
Registration Number
NCT06079151
Lead Sponsor
ADIR Association
Brief Summary

In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography. The research hypothesis is that nasal high-flow would increase cardiac output in patients with pulmonary hypertension. The concomitant echocardiography will allow to describe its sensibility to detect cardiovascular consequences of nasal high-flow.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up.
Exclusion Criteria
  • necessity of FiO2 >21% during right heart catheterization
  • intracardiac shunt
  • grade 4 tricuspid insufficiency
  • complete arrhythmia due to atrial fibrillation
  • Pregnant or breastfeeding women or women of childbearing age without an effective method of contraception
  • protected adult patient (tutorship or curatorship)
  • patient deprived of liberty by court or administrative decision
  • refusal of patient participation or consent
  • patient for whom the measurement of pulmonary arterial pressures during right heart catheterization is impossible
  • patient for whom, during the etiological assessment of pulmonary hypertension, the diagnosis of precapillary pulmonary hypertension cannot be confirmed and classified in groups 1, 3 or 4.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Nasal high-flow 30 L/min and then 50 L/minNasal high-flowThe patient will be placed successively under nasal high-flow 30 L/min during 20 min and then 50 L/min during 20 min.
Nasal high-flow 50 L/min and then 30 L/minNasal high-flowThe patient will be placed successively under nasal high-flow 50 L/min during 20 min and then 30 L/min during 20 min.
Primary Outcome Measures
NameTimeMethod
Cardiac outputDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

Secondary Outcome Measures
NameTimeMethod
cardiac outputDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30L/Min FiO2 21% as compared to room air

mean pulmonary arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

capillary wedge pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

pulse oxygen saturationDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

capillary wedge pressure measured by catheterization and echocardiography.During the intervention, at isotime

Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.

cardiac output measured by catheterization and echocardiography.During the intervention, at isotime

Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.

pulmonary vascular resistanceDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

central venous oxygen saturationDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

heart rateDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

systolic pulmonary arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

systolic arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

diastolic arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

mean arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

systolic ejection volumeDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

Consequences of nasal high-flow 50 and 30 L/min FiO2 21% on echocardiographic parameters.During the intervention, at isotime

Cardiac output, inferior vena cava diameter and collapsibiliy, systolic pulmoanry arterial pressure, tricuspid regurgitation velocity,tricuspid annular plane systolic excursion, right ventricule strain, tricuspid S wave, right on left ventricular telediastolic surface ratio, left ventricular ejection fraction, mitral doppler, mitral S wave, respiratory variability of E mitral wave

systolic pulmonary arterial pressure measured by catheterization and echocardiography.During the intervention, at isotime

Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.

right atrial pressure measured by catheterization and echocardiography.During the intervention, at isotime

Concordance and correlation of hemodynamic parameters measured by catheterization and echocardiography.

Right atrial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

diastolic pulmonary arterial pressureDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

respiratory rateDuring the intervention, at isotime

Changes measured during cardiac catheterization under nasal high-flow 30 and 50 L/min

Trial Locations

Locations (1)

ROUEN university hospital

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath